Long Term Follow-Up Of Abatacept, Post-Transplantation Cyclophosphamide and Sirolimus (AbaCyS) based Haploidentical Transplantation in Younger Patients with Nonmalignant Diseases

Haploidentical (Haplo) HCT for nonmalignant diseases (NMD) faces inherent challenges of both alloreactivity and graft failure. Building upon promising results from pilot studies, where abatacept was combined with post-transplantation cyclophosphamide (PTCy) and sirolimus (AbaCyS) in younger NMD patients undergoing haplo-HCT, we present the long-term outcomes of this protocol.

https://www.astctjournal.org/article/S2666-6367(24)00260-4/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - March 13, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Gitali Bhagawati, Bhudev Chandra Das, Prakash Baligar, Manoj Garg, Subhrajit Biswas, Suparno Chakrabarti Source Type: research